€17.00
8.01% day before yesterday
Xetra, Dec 05, 05:38 pm CET
Why the stock moved Why the stock moved Beta
ISIN
DE000A3ENQ51
Symbol
1SXP
Index

SCHOTT Pharma Stock price

€17.00
-1.62 8.70% 1M
-11.10 39.50% 6M
-8.16 32.43% YTD
-9.46 35.75% 1Y
-14.30 45.69% 3Y
-14.30 45.69% 5Y
-14.30 45.69% 10Y
-14.30 45.69% 20Y
Xetra, Closing price Fri, Dec 05 2025
-1.48 8.01%
ISIN
DE000A3ENQ51
Symbol
1SXP
Index

New AI Insights on SCHOTT Pharma Insights AI Insights on SCHOTT Pharma

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
€2.8b
Enterprise Value
€2.8b
Net debt
€45.1m
Cash
€41.2m
Shares outstanding
150.6m
Valuation (TTM | estimate)
P/E
17.5 | 16.8
P/S
2.9 | 2.8
EV/Sales
2.9 | 2.8
EV/FCF
56.3
P/B
3.2
Dividends
DPS
€0.16
Yield 1Y | 5Y
0.9% | 0.2%
Growth 1Y | 5Y
6.7% | -
Payout 1Y | 3Y
15.2% | 5.3%
Increased
2 Years
Financials (TTM | estimate)
Revenue
€975.7m | €1.0b
EBITDA
€265.3m | €281.1m
EBIT
€190.0m | €205.7m
Net Income
€146.9m | €152.8m
Free Cash Flow
€50.3m
Growth (TTM | estimate)
Revenue
2.9% | 5.5%
EBITDA
15.2% | 10.0%
EBIT
12.1% | 7.9%
Net Income
-2.2% | 2.1%
Free Cash Flow
120.2%
Margin (TTM | estimate)
Gross
33.7%
EBITDA
27.2% | 27.8%
EBIT
19.5%
Net
15.1% | 15.1%
Free Cash Flow
5.2%
Financial Health
Equity Ratio
54.8%
Return on Equity
18.9%
ROCE
17.0%
ROIC
12.9%
Debt/Equity
0.1
More
EPS
€1.0
FCF per Share
€0.3
Short interest
-
Employees
5k
Rev per Employee
€200.0k
Show more

Is SCHOTT Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

SCHOTT Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a SCHOTT Pharma forecast:

16x Buy
84%
2x Hold
11%
1x Sell
5%

Analyst Opinions

19 Analysts have issued a SCHOTT Pharma forecast:

Buy
84%
Hold
11%
Sell
5%

Financial data from SCHOTT Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
976 976
3% 3%
100%
- Direct Costs 646 646
3% 3%
66%
329 329
2% 2%
34%
- Selling and Administrative Expenses 128 128
2% 2%
13%
- Research and Development Expense 27 27
0% 0%
3%
265 265
15% 15%
27%
- Depreciation and Amortization 75 75
24% 24%
8%
EBIT (Operating Income) EBIT 190 190
12% 12%
19%
Net Profit 147 147
2% 2%
15%

In millions EUR.

Don't miss a Thing! We will send you all news about SCHOTT Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SCHOTT Pharma Stock News

AD HOC NEWS
3 days ago
Laut Analysten schwache Ziele von Schott Pharma DE000A3ENQ51 für 2026 und darüber hinaus haben die Aktien am Freitag belastet.
AD HOC NEWS
4 days ago
Der Pharmazulieferer Schott Pharma DE000A3ENQ51 kämpft weiter mit der Marktunsicherheit und nimmt sich für das neue Geschäftsjahr überraschend niedrige Umsatzziele vor.
More SCHOTT Pharma News

Company Profile

Head office Germany
CEO Andreas Reisse
Employees 4,775
Founded 2022
Website www.schott-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today